AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00564733 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Description: Given IV
Study NCT00564733 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: imaging biomarker analysis
Description: Correlative studies
Study NCT00138554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone
Description: pioglitazone 45 mg qd
Study NCT05021718 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthening exercises
Description: Back and hip strengthening exercises. The intensity of exercises was based on the exercise tolerance and pain thresholds of the individual subjects.
Study NCT05021718 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological therapy
Description: Naproxen (500 mg) and Baclofen (10 mg) tablet twice a day for three weeks
Study NCT05021718 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hot compression
Description: Hot moist compression from week 4 to week 6.
Study NCT05021718 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Activities to daily living instructions
Description: * Avoid forward bending.~* Avoid heavy weightlifting.~* Avoid prolong standing.~* Avoid prolong sitting.~* Use a plain firm bed.~* Lie down in a supine position.
Study NCT05021718 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activities to daily living instructions
Description: * Avoid forward bending.~* Avoid heavy weightlifting.~* Avoid prolong standing.~* Avoid prolong sitting.~* Use a plain firm bed.~* Lie down in a supine position.
Study NCT02186626 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WN/DEN4Δ30 Vaccine
Description: WN/DEN4Δ30 vaccine is a live attenuated, recombinant, chimeric virus. Dose: 10\^4 plaque-forming units (PFUs); delivered by subcutaneous injection in the deltoid region of the upper arm.
Study NCT02186626 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Delivered by subcutaneous injection in the deltoid region of the upper arm.
Study NCT02657265 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpineJack system
Description: Spine fracture management for traumatic vertebral compression fracture
Study NCT02657265 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conservative management
Description: Surgical corset according to measurement's impression, rigid corset with sternal support
Study NCT00209105 — intervention group
Intervention type: DRUG
Intervention: DEX-CRF stimulation test
Description: 1 ug/kg body weight of CRF for determining hpa response post dexamethasone ingestion
Study NCT00209105 — intervention group
Intervention type: BEHAVIORAL
Intervention: Psychosocial stress induction
Description: Laboratory stress induction, no drug administration
Study NCT00209105 — intervention group
Intervention type: PROCEDURE
Intervention: Brain imaging of sad mood , self-reference, reward
Description: Brain imaging
Study NCT00209105 — intervention group
Intervention type: BEHAVIORAL
Intervention: Acoustic startle
Description: No drugs involved
Study NCT03815734 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: motor imagery
Description: motor imagery during the postoperative immobilization period
Study NCT02826772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GT0918
Description: anti-tumor activity
Study NCT03724214 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Pre-hospital interventional care bundle
Description: The interventional care bundle will include pre-hospital and in-hospital components and core and adaptable components. All seven centres will implement the core pre-hospital and in-hospital components. Implementation of the adaptable components will be decided by the local team to optimise the interventional care bundle to the local environment.~Pre-hospital core components: 1) covering the bowel in clear plastic, 2) administering intravenous fluids, 3) keeping the neonate warm, 4) transferring to a study centre as soon as possible. This will be implemented as a pre-hospital gastroschisis care protocol to district and secondary level hospitals who refer patients with gastroschisis to the study centres.~Pre-hospital adaptable components: 1) the strategy for disseminating the pre-hospital gastroschisis care protocol.
Study NCT03724214 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: In-hospital interventional care bundle
Description: In-hospital core components: 1) use of a standardised care protocol, 2) neonatal resuscitation and ward care including intravenous access, intravenous fluids, maintenance of normothermia, appropriate antibiotics, regular monitoring and infection control, 3) gastroschisis reduction and sutureless closure using a preformed silo and avoidance of neonatal anaesthesia and surgery, 4) early establishment of breastfeeding and an enhanced enteral feeding programme.~In-hospital adaptable components: 1) administration of parenteral nutrition for neonates who have survived for 1-week in hospital, 2) maternal involvement in monitoring and basic management, 3) management of neonates with gastroschisis on the neonatal intensive care unit if available.
Study NCT02390128 — intervention group
Intervention type: OTHER
Intervention: observational only
Study NCT01208116 — intervention group
Intervention type: OTHER
Intervention: Cardiovascular events
Description: * Coronary intervention~* Infarction~* Congestive heart failure~* Stroke~* Cardiac death
Study NCT03836222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCS499
Description: MR tablet
Study NCT02167854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719
Study NCT02167854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LJM716
Study NCT02167854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRASTUZUMAB
Study NCT03414086 — intervention group
Intervention type: OTHER
Intervention: Healthy Control
Description: Ten healthy adult patients evaluating serum, PBMC's, and RNA.
Study NCT03414086 — intervention group
Intervention type: OTHER
Intervention: Myositis in Remission
Description: Ten patients (four who have polymyositis, six dermatomyositis) from our database who are followed in the Myositis Center. We will collect serum, PBMC's, and RNA samples will be obtained at baseline and at six months. Remission is defined as a global myositis disease activity score less than or equal to 1 on the MDAAT assessments with no new immunosuppressive drug or glucocorticoid use and no increase in dose of either in the preceding year.
Study NCT00936897 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibandronate
Description: Ibandronate 150mg PO QM (tablet)
Study NCT00936897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: denosumab 60mg SC Q6M (pre-filled syringe)
Study NCT01296282 — intervention group
Intervention type: DEVICE
Intervention: Medronics CRT Optivol Impedance Measurement
Description: Pacemaker
Study NCT01296282 — intervention group
Intervention type: DEVICE
Intervention: External Thoracic Impedance Measurement
Study NCT00662623 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: i-PAP
Description: Internet Intervention based on wireless telemonitoring of CPAP data and patient-centered, collaborative care
Study NCT00662623 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care (Standard Care)
Description: Pre-determined clinic visits and telephone support
Study NCT00499421 — intervention group
Intervention type: PROCEDURE
Intervention: Computed Tomography (CT) Scan
Description: CT scan of the prostate three times a week, just before the delivery of radiation.
Study NCT00127218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: any statin
Description: Participants will be provided a prescription for fluvastatin 80 mg to be taken on a daily basis, or they may continue their ongoing or any other cholesterol-lowering drugs such as pravastatin 80 mg daily, simvastatin 20 mg daily, atorvastatin up to 20 mg daily or rosuvastatin up to 20 mg daily for 18 months
Study NCT00127218 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: any statin
Description: Participants will be provided a prescription for fluvastatin 80 mg to be taken on a daily basis, or they may continue their ongoing or any other cholesterol-lowering drugs such as pravastatin 80 mg daily, simvastatin 20 mg daily, atorvastatin up to 20 mg daily or rosuvastatin up to 20 mg daily for 18 months
Study NCT00127218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: niacin
Description: long-acting niacin daily for 18 months
Study NCT00127218 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo pill daily for 18 months
Study NCT02752087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered SC
Study NCT02752087 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LY900014
Description: Administered SC
Study NCT02029014 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LAA closure system
Study NCT03881423 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium Bromide
Description: DEEP block to PTC 1-3
Study NCT03836222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trental
Description: comparator tablet
Study NCT01323751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACY-1215
Description: Liquid oral dose on Days 1-5 and 8-12 of 21-day treatment cycle
Study NCT05563376 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Univentricular Hearts
Description: Prevention when factors are recognized
Study NCT03423017 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Recording of data
Description: Recording during one hospitalization of 48 hours between birth and 2 months of life and one hospitalization of 24 hours between 6 and 10 months of life~* General data: age, term of birth, birth weight, gender, diseases, weight and size at recording, cranial perimeter, food, drugs : first and second visit~* Respiratory rate, respiratory signs, stridor : first and second visit~* 24h holter-ECG : first and second visit~* 24h impedance pH-metry : first visit~* Nocturne polysomnography : 50% prone position, 50% supine : sleep analyze, obstructive apnea hypopnea index (OAHI), central apnea index (CAI), periodical breathing, micro arousals index, non-nutritive swallowing analyze,(mental region electromyogram) : first and second visit~* 24 h gaz exchanges : mean, maximal PtcCO2 and % of time spent above 50 mmHg , SpO2 under 90%, 85% et 80% and desaturations index : first and second visit~* succimetry procedure : at first visit only between birth and 2 months
Study NCT03423017 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Recording of data
Description: Recording during one hospitalization of 48 hours between birth and 2 months of life~* General data: age, term of birth, birth weight, gender, diseases, weight and size at recording, cranial perimeter, food, drugs~* Respiratory rate, respiratory signs, stridor~* 24h holter-ECG~* 24h impedance pH-metry~* Nocturne polysomnography : 100% supine position : sleep analyze, obstructive apnea hypopnea index (OAHI), central apnea index (CAI), periodical breathing, micro arousals index, non-nutritive swallowing analyze,(mental region electromyogram)~* 24 h gas exchanges : mean, maximal PtcCO2 and % of time spent above 50 mmHg , SpO2 under 90%, 85% et 80% and desaturations index~* Succimetry procedure : at first visit only between birth and 2 months
Study NCT03961841 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: chemoradiation with weekly 5Fu and oxaliplatin
Description: 5Fu 225 mg/m2 IV daily continuous infusion；oxaliplatin 40 mg/m2/week
Study NCT03961841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perioperative mFLOT
Description: Perioperative docetaxel 50mg/m2；oxaliplatin 85 mg/m2; 5Fu 2.4g/m2 civ 48 hours; repeated every 2 weeks; total of 8 cycles
Study NCT03961841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perioperative FOLFOX
Description: Perioperative oxaliplatin 85 mg/m2; 5Fu 2.8g/m2 civ 48 hours; repeated every 2 weeks; total of 12 cycles
Study NCT03246724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triazolam
Description: This will be used for oral sedation. This capsule or a microcrystalline cellulose placebo capsule will be administered depending on the randomized treatment group.~Dose for BMI less than 35: 0.125 mg~Dose for BMI greater than or equal to 35: 0.25 mg
Study NCT02707445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Administration of conventional dual anti-platelet treatment (aspirin 100mg and clopidogrel 75mg daily) for minimum 3 months after percutaneous coronary intervention
Study NCT03426137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: 5mg Oxycodone in oral solution given every 3 hours
Study NCT03426137 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxycodone
Description: 5mg Oxycodone in oral solution given every 3 hours
Study NCT03426137 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketorolac
Description: toradol intravenous (IV) 30mg. Maintain toradol IV every 8 hours, round the clock. For patients with renal insufficiency, decrease toradol dose to 15mg every 8 hours. For patients over 65 years old, decrease toradol dose to 15 mg every 8 hours. After 24 hours, start oral NSAIDS every 8 hours round the clock when tolerating pain.
Study NCT03426137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: toradol intravenous (IV) 30mg. Maintain toradol IV every 8 hours, round the clock. For patients with renal insufficiency, decrease toradol dose to 15mg every 8 hours. For patients over 65 years old, decrease toradol dose to 15 mg every 8 hours. After 24 hours, start oral NSAIDS every 8 hours round the clock when tolerating pain.
Study NCT03426137 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral solutions containing only the carrier vehicle - a flavored syrup called OraSweet
Study NCT00737763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: efalizumab
Description: Enrollees randomized to efalizumab will receive the first dose of 0.7mg/kg subcutaneously given at enrollment, and 1.0 mg/kg subcutaneously weekly for 26 weeks self or family-administered after injection training. This is the FDA-approved initial and subsequent doses of efalizumab used for psoriasis treatment
Study NCT00737763 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Enrollees receiving placebo will be given a subcutaneous injection of equal volume and appearance to treatment on the same schedule.
Study NCT03190330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib 420 mg
Description: Ibrutinib capsule administered orally at a dose of 420 mg for CLL participants.
Study NCT03190330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib 560 mg
Description: Ibrutinib capsule administered orally at a dose of 560 mg for MCL participants.
Study NCT03246724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: This will be used for intravenous sedation. This injection or sodium chloride 0.9% will be administered depending on the randomized treatment group.~Dose for BMI less than 35: 1.0 mg~Dose for BMI greater than or equal to 35: 2.0 mg
Study NCT03920579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-386 formulation 2
Description: A single oral dose of 1 tablet under fasting conditions for each period
Study NCT02648100 — intervention group
Intervention type: OTHER
Intervention: biomarker study
Study NCT03246724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microcrystalline Cellulose
Description: This will be used for the oral placebo. This capsule or a triazolam capsule will be administered depending on the randomized treatment group.~Dose for BMI less than 35: 1 capsule~Dose for BMI greater than or equal to 35: 2 capsule
Study NCT03246724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium chloride 0.9%
Description: This will be used for the intravenous placebo.This injection or midazolam will be administered depending on the randomized treatment group.~Dose for BMI less than 35: volume to match volume of active intravenous medication~Dose for BMI greater than or equal to 35: volume to match volume of active intravenous medication
Study NCT03452982 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sentinel node technique
Description: Injection of a tracer in the stump of the infundibulo-pelvic ligament and uterus-ovary for sentinel node detection.
Study NCT00476385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatropine
Description: subcutaneous injections, 20 % less than the dosage of Maxomat 1.3 mg
Study NCT05655416 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endovenous chemical ablation with Trendelenburg's operation (eCAT)
Description: Endovenous chemical ablation with trendelenburg's operation (e CAT) is a method for the treatment of varicose veins
Study NCT00112840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCI-779
Description: CCI-779 is taken IV on days 1, 8, 15, 22 of a 28-day cycle. Dose level is dependent on phase.
Study NCT00112840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab is taken IV on Days 1 and 15 of a 28-day cycle. Dose Level determined by phase.
Study NCT04306770 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OPTIMUM programme
Description: OPTIMUM programme encompass of telehealth service to support the patient. Study participants will be given devices (Bluetooth-enabled blood pressure machine, weighing scale and glucometer) to monitor their parameters at home. Care team will use the Phillips Vital Health to perform tele-monitoring, tele-management (individualized on-line health coaching and timely interventions), and to deliver education content.
Study NCT04978922 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Machine Learning: ML (Artificial Intelligence System)
Description: To applicate an artificial intelligence system (Machine Learning: ML) on an active telemonitoring programme of readmitted COPD patients (TelEPOC)
Study NCT01610414 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Herpes Zoster vaccine GSK1437173A
Description: 2 doses administered intramuscularly (IM) in deltoid region of non-dominant arm
Study NCT01610414 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 doses administered IM in deltoid region of non-dominant arm
Study NCT03180294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion 150 mg XL
Description: By mouth
Study NCT03180294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: By mouth
Study NCT03180294 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: By mouth
Study NCT01926652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: candesartan cilexetil 32mg, amlodipine 10mg
Description: Part A: Treatment A (candesartan), Treatment B (candesartan + amlodipine) 2-period, 2-treatment crossover.~Part B: Treatment A (Amlodipine), Treatment B (candesartan + amlodipine) 2-period, 2-treatment crossover.
Study NCT01809327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Description: One 100 mg capsule taken orally (by mouth) once daily either before the morning meal (for the Canagliflozin 100 mg arm) or with the evening meal (for the Canagliflozin 100 mg + Metformin XR arm).
Study NCT01809327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Description: One 300 mg capsule taken orally (by mouth) once daily either before the morning meal (for the Canagliflozin 300 mg arm) or with the evening meal (for the Canagliflozin 300 mg + Metformin XR arm).
Study NCT01809327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin XR
Description: One 500 mg tablet (Day 1 up to week 1); two 500 mg tablets (Week 1 up to Week 3); three 500 mg tablets (Week 3 to Week 6); four 500 mg tablets (Week 6 to Week 9). Tablets will be administered with the evening meal.
Study NCT01802294 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parenting Program
Description: Goal of the program is reduction in child behavior problems in high-risk South African families. Program will be delivered to caregivers responsible for the wellbeing of the child.~Program activities will be delivered over 12 weekly group sessions with additional individualized in-home sessions. The groups (n = 15 participants per group) will meet weekly with community facilitators (n = 2 per group). Parenting skills will be developed during the sessions through role-plays, group-discussion, storytelling, and home practice activities.~The program is manualized in isiXhosa.
Study NCT04802928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid 300 milligram
Description: Tablets 150 milligram b.i.d.
Study NCT04802928 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03712670 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: monthly intravitreal injections
Study NCT03712670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: monthly intravitreal injections
Study NCT03712670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pranoprofen
Description: 0.1% pranoprofen 3 times a day topical eye drops administration
Study NCT03712670 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carotenoids
Description: daily supplementation of nutraceutical tablets containing the AREDS2 formulation
Study NCT00779818 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical acupuncture
Description: Treatment by electrical acupuncture